Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 2
2004 2
2006 2
2008 1
2009 1
2010 2
2011 2
2012 2
2013 1
2014 1
2016 1
2017 4
2018 2
2019 3
2020 6
2021 1
2022 3
2023 3
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Results by year

Filters applied: . Clear all
Page 1
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer.
Powles T, Valderrama BP, Gupta S, Bedke J, Kikuchi E, Hoffman-Censits J, Iyer G, Vulsteke C, Park SH, Shin SJ, Castellano D, Fornarini G, Li JR, Gümüş M, Mar N, Loriot Y, Fléchon A, Duran I, Drakaki A, Narayanan S, Yu X, Gorla S, Homet Moreno B, van der Heijden MS; EV-302 Trial Investigators. Powles T, et al. N Engl J Med. 2024 Mar 7;390(10):875-888. doi: 10.1056/NEJMoa2312117. N Engl J Med. 2024. PMID: 38446675 Clinical Trial.
Development and Independent Validation of a Prognostic Gene Expression Signature Based on RB1, PTEN, and TP53 in Metastatic Hormone-sensitive Prostate Cancer Patients.
Jiménez N, Garcia de Herreros M, Reig Ò, Marín-Aguilera M, Aversa C, Ferrer-Mileo L, García-Esteve S, Rodríguez-Carunchio L, Trias I, Font A, Rodriguez-Vida A, Climent MÁ, Cros S, Chirivella I, Domènech M, Figols M, Carles J, Suárez C, Herrero Rivera D, González-Billalabeitia E, Cívico C, Sala-González N, Ruiz de Porras V, Ribal MJ, Prat A, Mellado B. Jiménez N, et al. Among authors: domenech m. Eur Urol Oncol. 2024 Mar 1:S2588-9311(24)00025-7. doi: 10.1016/j.euo.2023.12.012. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38429210 Free article.
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, Özgüroğlu M, Valderrama BP, Laguerre B, Basso U, Triantos S, Akapame S, Kean Y, Deprince K, Mukhopadhyay S, Loriot Y; THOR cohort 2 investigators. Siefker-Radtke AO, et al. Ann Oncol. 2024 Jan;35(1):107-117. doi: 10.1016/j.annonc.2023.10.003. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871702 Clinical Trial.
Predictive signature of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer integrating mRNA expression, taxonomic subtypes, and clinicopathological features.
Font A, Domenech M, Ramirez JL, Marqués M, Benítez R, Ruiz de Porras V, Gago JL, Carrato C, Sant F, Lopez H, Castellano D, Malats N, Calle ML, Real FX. Font A, et al. Among authors: domenech m. Front Oncol. 2023 Aug 3;13:1155244. doi: 10.3389/fonc.2023.1155244. eCollection 2023. Front Oncol. 2023. PMID: 37588099 Free PMC article.
Prevalence of immune-related adverse events and anti-tumor efficacy in advanced/metastatic urothelial carcinoma following immune-checkpoint inhibitor treatment.
Morales-Barrera R, Villacampa G, Vidal N, Figols M, Giner J, Bonfill T, Suárez C, Díaz N, Mateo J, González M, Domenech M, Puente J, Carles J. Morales-Barrera R, et al. Among authors: domenech m. Clin Transl Oncol. 2023 Dec;25(12):3556-3564. doi: 10.1007/s12094-023-03213-6. Epub 2023 May 22. Clin Transl Oncol. 2023. PMID: 37217634
Transcriptional Profile Associated with Clinical Outcomes in Metastatic Hormone-Sensitive Prostate Cancer Treated with Androgen Deprivation and Docetaxel.
Jiménez N, Reig Ò, Marín-Aguilera M, Aversa C, Ferrer-Mileo L, Font A, Rodriguez-Vida A, Climent MÁ, Cros S, Chirivella I, Domenech M, Figols M, González-Billalabeitia E, Jiménez Peralta D, Rodríguez-Carunchio L, García-Esteve S, Garcia de Herreros M, Ribal MJ, Prat A, Mellado B. Jiménez N, et al. Among authors: domenech m. Cancers (Basel). 2022 Sep 29;14(19):4757. doi: 10.3390/cancers14194757. Cancers (Basel). 2022. PMID: 36230681 Free PMC article.
Nomogram based on baseline clinicopathological characteristics for predicting bladder cancer-specific survival to neoadjuvant chemotherapy in muscle-invasive bladder cancer.
Font A, Domenech M, Buisan O, Lopez H, González A, Etxaniz O, Matas M, Elias X, Gomez M, Figols M, Horneros J, Pardo JC, Notario L, Ruiz de Porras V, Perez I, Areal J, Esteve A. Font A, et al. Among authors: domenech m. World J Urol. 2022 Nov;40(11):2627-2634. doi: 10.1007/s00345-022-04147-4. Epub 2022 Sep 15. World J Urol. 2022. PMID: 36107212
SEOM-SOGUG clinical guideline for localized muscle invasive and advanced bladder cancer (2021).
Valderrama BP, González-Del-Alba A, Morales-Barrera R, Peláez Fernández I, Vázquez S, Caballero Díaz C, Domènech M, Fernández Calvo O, Gómez de Liaño Lista A, Arranz Arija JÁ. Valderrama BP, et al. Among authors: domenech m. Clin Transl Oncol. 2022 Apr;24(4):613-624. doi: 10.1007/s12094-022-02815-w. Epub 2022 Mar 26. Clin Transl Oncol. 2022. PMID: 35347572 Free PMC article.
Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer.
Jiménez N, Reig Ò, Montalbo R, Milà-Guasch M, Nadal-Dieste L, Castellano G, Lozano JJ, Victoria I, Font A, Rodriguez-Vida A, Carles J, Suárez C, Domènech M, Sala-González N, Fernández PL, Rodríguez-Carunchio L, Díaz S, Prat A, Marín-Aguilera M, Mellado B. Jiménez N, et al. Among authors: domenech m. Front Oncol. 2020 Nov 2;10:594023. doi: 10.3389/fonc.2020.594023. eCollection 2020. Front Oncol. 2020. PMID: 33224888 Free PMC article.
40 results